3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
12
Carcinoma, Hepatocellular
8
Small Cell Lung Carcinoma
7
Cholangiocarcinoma
7
Neoplasms
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms by Site
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Vaccinia
1
Unresectable Hepatocellular Carcinoma
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
durvalumab
1
Immunotherapy
1
Bevacizumab
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
durvalumab
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled